Business context and reporting period
PharmaCyte Biotech, Inc. is a pre-revenue, clinical-stage biotechnology company developing cancer and diabetes therapies using its Cell-in-a-Box live-cell encapsulation technology. The filing is a Form 10-K for the fiscal year ended April 30, 2015—not a calendar 2014 fourth-quarter report as the request metadata suggests. It reports annual results and unaudited quarterly results.
Financial performance and liquidity
| Metric | Year ended April 30, 2015 | Year ended April 30, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $13.70 million | $18.98 million |
| Operating loss | $13.70 million | $18.98 million |
| Other income (expense), net | $2.84 million income | $8.27 million expense |
| Net loss | $10.85 million | $27.25 million |
| Net loss per share | $0.02 | $0.05 |
| Net cash used in operations | $4.56 million | $1.55 million |
Operating expenses fell 28%, primarily because of lower stock-based compensation; research and development expense rose to $3.48 million from $0.32 million. The smaller net loss also reflected $3.34 million of non-cash gain from recovery of shares in settlements, partly offset by a $0.49 million non-cash derivative loss. Prior-year results included substantial non-cash charges related to preferred-stock conversion and debt settlement.
At April 30, 2015, cash was $2.70 million, current assets $2.82 million, current liabilities $2.01 million, and working capital approximately $0.81 million. Total assets were $7.95 million and total liabilities $2.01 million; the balance sheet reports no long-term debt. Accumulated deficit was $79.55 million. Cash declined by $0.92 million during the year. Financing provided $3.64 million, principally from common-stock sales, while operating activities used $4.56 million.
Management reported approximately $250,000 in monthly cash expenditures and stated that financing was expected to fund operations through July 31, 2016. Cash figures after year-end vary within the filing: it reports approximately $3.03 million as of July 27, 2015, while a subsequent-events note reports $2.9 million following share sales. The company has no open credit lines and expects to rely on additional capital, including equity issuance.
Material changes and business developments
- The company continued preparations for a Phase 2b pancreatic-cancer trial in Australia, planned with a contract research organization, and U.S. studies of pain and malignant ascites. Management anticipated trial commencement in the latter part of 2015, subject to funding and readiness.
- Research continued on encapsulated Melligen insulin-producing cells and cannabinoid-based therapies. No product had regulatory marketing approval, and the diabetes and cannabinoid programs remained preclinical or earlier-stage.
- The company entered a cannabis-technology license agreement requiring a $2.0 million upfront payment. It had paid $1.0 million by year-end and $1.3 million by the report date; the parties agreed in principle to defer the balance to December 31, 2015, but the amendment was still being documented. The agreement also provides for an $800,000 manufacturing setup fee, production costs, royalties and development milestones.
- Common shares outstanding increased from 690.6 million to 732.8 million during the year. The company also granted substantial options and issued shares for compensation and services. Potential options and warrants create additional dilution risk.
Outlook, risks and unusual items
There is no formal revenue or earnings guidance. Management expects continued losses and says additional financing is needed to fund development. The financial statements are prepared on a going-concern basis; the company warns that failure to raise capital could delay or end planned trials and could force it to modify or cease operations.
Key risks include clinical and regulatory uncertainty; reliance on third-party researchers, CROs and manufacturers; competition; dependence on key consultants and license partners; and the possibility that prior small, open-label pancreatic-cancer trial results will not be replicated. The company’s comparisons of its earlier trial results with standard treatments are not proof of efficacy: the trials were small and not designed to establish statistically significant benefit.
Management identified material weaknesses in internal controls, including ineffective governance, inadequate documentation and segregation of duties, and deficiencies in information-technology controls. Management and the auditor concluded internal control over financial reporting was ineffective as of April 30, 2015; the auditor issued an adverse opinion on internal controls but an unqualified opinion on the financial statements. The company reported no material pending litigation.
Important facts for investors to verify
- Current cash, monthly burn rate, and whether financing is sufficient to reach the stated July 2016 runway; reconcile the differing post-year-end cash figures.
- Status and timing of the Australian Phase 2b trial and planned U.S. studies, including funding, regulatory clearances, enrollment, and trial design.
- Whether the cannabis-license payment amendment was finalized and what remaining license, manufacturing, royalty, and milestone obligations require funding.
- Progress in remediating internal-control material weaknesses and any subsequent audit or restatement developments.
- Share-count dilution from future equity sales, outstanding options and warrants, and compensation-related issuances.